Additionally, the administration of the monoclonal antibody Anakinra, a recombinant IL-1 receptor antagonist that inhibits both IL-1β and IL-1α, in patients with STEMI reduced mortality and incidence of newly diagnosed HF, compared with a placebo [55]. This evidence concerns the gene IL1B and hydrops fetalis.